Publikationen in Zusammenarbeit mit Forschern von Fox Chase Cancer Center (36)

2023

  1. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

    British Journal of Cancer, Vol. 128, Núm. 12, pp. 2283-2294

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

2015

  1. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer

    Clinical Cancer Research, Vol. 21, Núm. 3, pp. 652-657

2014

  1. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

    British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477

  2. The IASLC/ITMIG thymic epithelial tumors staging project: Proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors

    Journal of Thoracic Oncology, Vol. 9, Núm. 9, pp. S65-S72

  3. The IASLC/ITMIG thymic epithelial tumors staging project: Proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors

    Journal of Thoracic Oncology, Vol. 9, Núm. 9, pp. S81-S87

  4. The IASLC/ITMIG thymic epithelial tumors staging project: Proposals for the T component for the forthcoming (8th) edition of the TNM classification of malignant tumors

    Journal of Thoracic Oncology, Vol. 9, Núm. 9, pp. S73-S80

2012

  1. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy

    Journal of Clinical Oncology, Vol. 30, Núm. 6, pp. 631-636

2002

  1. Elevated JNK activation contributes to the pathogenesis of human brain tumors

    Oncogene, Vol. 21, Núm. 33, pp. 5038-5046

  2. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors

    American Journal of Pathology, Vol. 160, Núm. 2, pp. 441-447

1999

  1. Expression of OVCA1, a candidate tumor suppressor, is reduced in tumors and inhibits growth of ovarian cancer cells

    Cancer Research, Vol. 59, Núm. 19, pp. 4973-4983

1996

  1. A Grb2-associated docking protein in EGF- and insulin-receptor signalling

    Nature, Vol. 379, Núm. 6565, pp. 560-564

1995

  1. Frequent Expression of a Mutant Epidermal Growth Factor Receptor in Multiple Human Tumors

    Cancer Research, Vol. 55, Núm. 23, pp. 5536-5539

1994

  1. Effects of provirus integration in the Tpl-1/Ets-1 locus in Moloney murine leukemia virus-induced rat T-cell lymphomas: Levels of expression, polyadenylation, transcriptional initiation, and differential splicing of the Ets-1 mRNA

    Journal of Virology, Vol. 68, Núm. 4, pp. 2320-2330

1993

  1. CHROMOSOMAL LOCALIZATION OF THE OX-44 (CD53) LEUKOCYTE ANTIGEN GENE IN MAN AND RODENTS

    CYTOGENETICS AND CELL GENETICS, Vol. 64, Núm. 3-4, pp. 217-221

1991

  1. MAPPING OF THE OX44 HUMAN-LEUKOCYTE ANTIGEN GENE TO 1P12-P13 BY FLUORESCENCE INSITU HYBRIDIZATION

    CYTOGENETICS AND CELL GENETICS

  2. The Rat Leukocyte Antigen MRC OX-44 Is a Member of a New Family of Cell Surface Proteins Which Appear to Be Involved in Growth Regulation

    Molecular and Cellular Biology, Vol. 11, Núm. 5, pp. 2864-2872

  3. Virus-host interactions and the pathogenesis of murine and human oncogenic retroviruses

    Current Topics in Microbiology and Immunology, Vol. 171, pp. 96-171

1990

  1. Activation of multiple genes by provirus integration in the Mlvi-4 locus in T-cell lymphomas induced by Moloney murine leukemia virus

    Journal of Virology, Vol. 64, Núm. 5, pp. 2236-2244